



MEDTECS INTERNATIONAL CORPORATION LIMITED
(Incorporated in Bermuda)

MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

1. INTRODUCTION

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 3 December 2024, 27 December 2024, 17 January 2025 and 24 January 2025 (the "**Announcements**") in relation to, among others, the Winding Up Application and the Court Order in respect of Resilient Medical Pte. Ltd. ("**Resilient Medical**").

Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings ascribed to them in the Announcements.

2. MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

Pursuant to Rule 704(22) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited, the Board wishes to update shareholders that since the Company's previous monthly update announcement on 24 January 2025, there have been no further material developments that could have a significant impact on the Company's financial position. As disclosed in the previous monthly update, the Company intends to file a proof of debt with the Liquidator and there have been no negotiations between the Company and the Company's principal bankers or trustee, as the Liquidator is still in the process of gathering documents.

3. FINANCIAL IMPACT

As at the date of this announcement, the Company is still assessing the impact of the Court Order on the net tangible assets per share of the Company and the earnings per share of the Company for the current financial year ending 31 December 2025 as such impact would be affected by the valuation and methodology of the distribution of assets to be determined by the Liquidator. In the event that there is a material impact on the Group's financials or any further material development on this matter, the Company will make a separate announcement in due course.

The Company will also release further announcements to update its shareholders as and when there are material developments in relation to the winding up of Resilient Medical in between the monthly updates.

4. CAUTION IN TRADING

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company are advised to refrain from taking any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers,

bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

Submitted by Mr Clement Yang, Executive Chairman, on 27 February on the SGX-ST.

*This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**").*

This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact persons for the Sponsor are Ms Evelyn Wee (Telephone Number: +65 6232 0724) and Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.